Posters reported the prevalence of autoimmune comorbidities among patients with vitiligo, demonstrating the need for earlier screenings and updated clinical guidelines. The first poster 1 described a ...

Teva has penned a second pact with Royalty Pharma, this time securing up to $500 million to support the clinical development ...

Teva Pharmaceuticals TEVA announced a funding agreement with Royalty Pharma plc RPRX, under which the latter will provide up to $500 million to accelerate the development of Teva’s anti-IL-15 antibody ...

Incyte’s The Power of Choice campaign was supported by two 2025 MM+M Agency 100 honorees: Klick and Real Chemistry.

Model Winnie Harlow opened up to PEOPLE about living with vitiligo, an autoimmune condition that causes loss of skin pigmentation Harlow is working to demystify vitiligo through a new partnership with ...

This article is sponsored by Incyte. Vitiligo is a chronic autoimmune condition that manifests as white patches of depigmented skin, or a complete loss of color, on affected areas of the body. The ...

It was found that adding NB-UVB light therapy to ruxolitinib (Opzelura) 1.5% cream helped many vitiligo patients who did not respond early to treatment achieve faster and more noticeable skin ...

Please provide your email address to receive an email when new articles are posted on . Kim Kardashian stated that she passed vitiligo to one of her sons. John E. Harris, MD, PhD, discusses the ...

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 ...